Loading viewer...
investor_presentation
Format: PDF investor_presentation
2018 ASTRO Investor Meeting October 23, 2018 Transforming Cancer Care
FOR INVESTOR USE ONLY
Welcome & Introductions
SVP, Investor Relations, Corporate Planning & Segment Finance
Varian Overview & Strategic Framework
Dow WilsonPresident and Chief Executive Officer
Innovations in Oncology
Kolleen KennedyChief Growth Officer and President , Proton Solutions
Chris TothPresident, Oncology Systems
SVP, Oncology Software Solutions
New Horizons in Cancer Care
Dee Khuntia, MDChief Medical Officer
Dow WilsonPresident and Chief Executive Officer
Questions & AnswersThis presentation is intended exclusively for investors.
It is not intended for use in Sales or Marketing.
Forward- Looking Statements
Except forhistorical information, thispresentation contains forward -looking statements within themeaning ofthePrivate Securities Litigation Reform Actof1995 .Statements
concerning industry outlook, including growth drivers, future trends incancer incidence andtrends incancer treatment needs, demand, innovation andgrowth opportunities ;Varian
Medical System, Inc.’s(”Varian” orthe“company”) future orders, revenues, backlog orearnings growth ;future financial results ;market acceptance ofortransition tonew products or
technology such asourEdge®radiosurgery system, TrueBeam®,HyperArcTM,360OncologyTM,HALCYONTM,image -guided radiation therapy, stereotactic radiosurgery andproton
therapy, and any statements using theterms “could”, “believe”, “expect”, “outlook”, “anticipate”, ”vision”, “estimate”, “future”, “horizon”, “aiming”, “driving”, “target” orsimilar
statements areforward -looking statements thatinvolve risks anduncertainties thatcould cause thecompany’s actual results todiffer materially from those anticipated .Such risks
anduncertainties include global economic conditions andchanges totrends forcancer treatment regionally ;new andpotential future tariffs oraglobal trade war;theimpact of
changes totheAffordable Health Care forAmerica Act(including excise taxes onmedical devices) and anyfurther healthcare reforms (including changes toMedicare and
Medicaid), and/or changes tothird-party reimbursement levels ;currency exchange rates andtaxrates ;theimpact oftheTaxCuts andJobs Act;demand forthecompany’s products ;
thecompany’s ability todevelop, commercialize, anddeploy new products ;thecompany’s ability tomeet Food andDrug Administration (FDA) andother regulatory requirements for
product clearances ortocomply with FDA andother regulatory regulations orprocedures, changes intheregulatory environment, including with respect toFDA requirements ;the
company’s assessment ofthegoodwill associated withitsproton business, challenges associated withthesuccessful commercialization ofthecompany’s proton business ;therisks
associated with providing financing fortheconstruction andstart-upoperations ofproton therapy centers ;theeffect ofadverse publicity ;thecompany’s reliance onsole orlimited -
source suppliers ;thecompany’s ability tomaintain orincrease margins ;theimpact ofcompetitive products andpricing ;thepotential loss ofkeydistributors orkeypersonnel ;
Preview truncated — download the full document for the complete content.
conference
27 Pages
investor_presentation
38 Pages
EOG Resources